In January 2025, the FDA issued a significant guidance update that allows drug and device manufacturers to share scientific information about off-label uses of their products with healthcare providers (HCPs). This new framework, known as the SIUU guidance, permits sales personnel to discuss off-label data during visits, post such information on company websites, and utilize a broader range of evidence types. While this marks a liberalization in communication policies, companies must meticulously comply with the regulations and understand the nuances of safe harbor provisions. Notably, firms are cautioned against blurring promotional and scientific communications to avoid jeopardizing patient safety and regulatory compliance. Overall, the guidance aims to balance the need for HCPs to access clinical information while ensuring that manufacturers adhere to patient protection standards.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.lifescienceleader.com/doc/a-door-ajar-fda-s-final-siuu-guidance-and-off-label-communications-0001
